Overview

* Joint Q3 revenue grows 6% to $13.4 mln, slightly beating analyst expectations

* Net income improves to $855,000 from a loss of $3.2 mln in Q3 2024

* Board authorizes additional $12 mln for share repurchases

Outlook

* Company updates 2025 system-wide sales guidance to $530 mln-$534 mln from $530 mln-$550 mln

* Comp sales now expected to range from -1% to 0% for 2025

* Company maintains 2025 Adjusted EBITDA guidance at $10.8 mln-$11.8 mln

Result Drivers

* REFRANCHISING STRATEGY - Co is executing strategies to refranchise its corporate portfolio, aiming to improve financial performance and become a pure-play franchisor

* DIGITAL MARKETING - Increased digital marketing efforts, including SEO and AI-search, are part of initiatives to enhance patient acquisition and brand message

* TECHNOLOGY INVESTMENT - Co enhanced its mobile app and initiated a three-tiered pricing pilot to improve patient experience and operational efficiency

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $13.40 $13.36

Revenue Beat* mln mln (5

Analysts

)

Q3 EPS $0.06

Q3 $3.30

Adjusted mln

EBITDA

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Joint Corp ( JYNT ) is $16.00, about 48.2% above its November 5 closing price of $8.29

* The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 36 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)